Related Experiment Video

Updated: Feb 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?

Ryan Phillips1, Piet Ost2, Phuoc T Tran1,3

  • 1Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, MD, USA.

Future Oncology (London, England)
|October 12, 2017
PubMed
Abstract

No abstract available in PubMed .

Keywords:
castration-resistant prostate cancerneoplasm metastasisneoplasm recurrenceoligometastasisprostate cancerstereotactic ablative radiotherapystereotactic body radiation therapy

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

907
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.5K

Related Experiment Videos

Last Updated: Feb 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

907
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

Articles linked to this work by shared authors, journal, and citation graph.

APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial.

JCO precision oncology·2026

Metastasis-directed therapy in oligoprogressive prostate cancer: current evidence and future directions.

Annals of palliative medicine·2026

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology·2026

A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413.

Cancers·2026

Twist1 overexpression models an aggressive subtype of pancreatic ductal adenocarcinoma in vivo.

Lab animal·2026

High frequency of RB1 mutations p16 positive early stage oropharyngeal carcinoma: A genomic and transcriptomic analysis.

Oral oncology·2026

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

Future oncology (London, England)·2026

The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?

Future oncology (London, England)·2026

Study protocol on quality of life and erectile function recovery in unfavorable intermediate-risk prostate cancer: REDI-CaP trial.

Future oncology (London, England)·2026

PSMA-PET/mpMRI-guided focal dose-escalated stereotactic body radiotherapy for localized prostate cancer: study protocol for a prospective, randomized controlled trial.

Future oncology (London, England)·2026

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

Future oncology (London, England)·2026

Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences.

Future oncology (London, England)·2026

Comparison of Esophageal Dose Parameters in Breast Cancer Radiotherapy With and Without Esophageal Contouring.

Cureus·2026

Staged Flexible Transurethral Lithotripsy After Robot-Assisted Partial Nephrectomy for Concomitant Renal Cell Carcinoma and Ipsilateral Nephrolithiasis: A Case Report.

Cureus·2026

Mechanistic insights into Strontium-90 superficial radiotherapy in keloids: senescence-associated changes and ECM remodeling across cell-matrix scales.

Frontiers in pharmacology·2026

Three-Dimensional Soft Tissue Reconstructive Planning in Orthoplastic Oncology: A Systematic Review.

Cureus·2026

[Role and Potential Mechanisms of Peroxisome Proliferator-Activated Receptor α in Ultraviolet B Radiation-Induced Skin Damage].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2026

A clinical evaluation of HyperSight CBCT enhanced offline adaptive breast radiotherapy.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us